P-Selectin Glycoprotein Ligand 1: A Potential HIV-1 Therapeutic Target

Frontiers in Immunology

Silvere D. Zaongo¹  Fangzhou Song¹  Vijay Harypursat³  Yanqiu Liu³  Yaokai Chen³  Huan Xia⁴  Ping Ma⁴ 

[1] Basic Medicine College, Chongqing Medical University, Chongqing, China;Department of Infectious Diseases, Tianjin Second People’s Hospital, Tianjin, China;Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China;School of Medicine, Nankai University, Tianjin, China;

关键词: P-selectin glycoprotein ligand 1;    HIV;    therapeutic target;    infection;    inflammation;   

DOI  :  10.3389/fimmu.2021.710121

来源: DOAJ

【 摘 要 】

Antiretroviral therapy (ART), which is a life-long therapeutic option, remains the only currently effective clinical method to treat HIV-1 infection. However, ART may be toxic to vital organs including the liver, brain, heart, and kidneys, and may result in systemic complications. In this context, to consider HIV-1 restriction factors from the innate immune system to explore novel HIV therapeutics is likely to be a promising investigative strategy. In light of this, P-selectin glycoprotein ligand 1 (PSGL-1) has recently become the object of close scrutiny as a recognized cell adhesion molecule, and has become a major focus of academic study, as researchers believe that PSGL-1 may represent a novel area of interest in the research inquiry into the field of immune checkpoint inhibition. In this article, we review PSGL-1’s structure and functions during infection and/or inflammation. We also outline a comprehensive review of its role and potential therapeutic utility during HIV-1 infection as published in contemporary academic literature.

【 授权许可】

Unknown